Cancer Treatment Bill

Publication
Article
OncologyONCOLOGY Vol 14 No 9
Volume 14
Issue 9

Politics may have a little something to do with nearing congressional passage of a bill (S. 662/H.R. 1070) that would allow states to provide medical treatment via Medicaid for low-income women who have been diagnosed with breast or cervical cancer through the CDC’s National Breast and Cervical Cancer Early Detection Program. In the decade that the program has existed, about 1 to 1.5 million women have been screened, with 6,000 cases of breast cancer and 500 of cervical cancer being found. But once diagnosed, these women, whose incomes are too high for Medicaid and who do not have personal health insurance, have to search for “donated” medical care. The Senate bill, originally sponsored by now-deceased Sen. John Chafee, passed the Senate Finance Committee at the end of June. It now goes to the floor, where passage seems assured. The House bill, which passed in May, is sponsored by Rep. Rick Lazio (R-NY), now knee-deep in a high-profile New York Senate race with Hillary Clinton. House Republicans are eager to give Lazio something to talk about. The cost of the measure will be about $50 million a year to the federal government, which contributes about $3 for each $1 that states contribute to the Medicaid pot. Nonetheless, the Senate Finance Committee was concerned enough about a potential precedent to include in its report a sentence saying that this benefit “shall not be viewed as a precedent for extending Medicaid eligibility body-part by body-part.”

Politics may have a little something to do with nearing congressional passage of a bill (S. 662/H.R. 1070) that would allow states to provide medical treatment via Medicaid for low-income women who have been diagnosed with breast or cervical cancer through the CDC’s National Breast and Cervical Cancer Early Detection Program. In the decade that the program has existed, about 1 to 1.5 million women have been screened, with 6,000 cases of breast cancer and 500 of cervical cancer being found. But once diagnosed, these women, whose incomes are too high for Medicaid and who do not have personal health insurance, have to search for “donated” medical care. The Senate bill, originally sponsored by now-deceased Sen. John Chafee, passed the Senate Finance Committee at the end of June. It now goes to the floor, where passage seems assured. The House bill, which passed in May, is sponsored by Rep. Rick Lazio (R-NY), now knee-deep in a high-profile New York Senate race with Hillary Clinton. House Republicans are eager to give Lazio something to talk about. The cost of the measure will be about $50 million a year to the federal government, which contributes about $3 for each $1 that states contribute to the Medicaid pot. Nonetheless, the Senate Finance Committee was concerned enough about a potential precedent to include in its report a sentence saying that this benefit “shall not be viewed as a precedent for extending Medicaid eligibility body-part by body-part.”

Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Despite the addition of a TIGIT inhibitor to a checkpoint inhibitor resulting in high levels of safety, there is no future for that combination alone, according to Ritu Salani, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Following the results of the phase 3 CALLA trial, Jyoti S. Mayadev, MD, discusses the importance of global clinical multidisciplinary efforts in the locally advanced cervical cancer space.
Related Content